VANCOUVER, British Columbia — AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) platform in two poster presentations at the American Society for Cancer Research (AACR) ...

EVOTEC LICENSES PANCELLA'S STATE-OF-THE-ART IPSC TECHNOLOGIES IACT STEALTH CELL™ AND FAILSAFE™ FOR USE IN CELL THERAPY ACCESS TO PANCELLA'S TECHNOLOGY HAS THE POTENTIAL TO ENABLE SAFE AND OFF ...

AbCellera (Nasdaq: ABCL) today announced new data on its T-cell engager (TCE) platform, to be presented as a poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting at the ...

NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) — Cell BioEngines, Inc. (“Cell BioEngines” or the “Company”), a clinical-stage biotechnology company developing a universal ‘plug-and-play’ allogeneic stem ...

Phase 1 Clinical Trial Expected to Begin in the Second Half of 2021GAITHERSBURG, Md., April 06, 2021 (GLOBE NEWSWIRE) -- Arcellx, a privately held clinical-stage biopharmaceutical company, today ...

(RTTNews) - IN8bio, Inc. (INAB) announced the launch of its next-generation Gamma-Delta T-cell engager or TCE platform INB-600, designed to overcome the limitations of existing Gamma-Delta TCE ...

Curia signs license agreement with MilliporeSigma to support production of proteins and antibodiesALBANY, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development ...

“The Lightcast Envisia platform is truly one of a kind, enabling us to analyze single-cell functional activity in real time,” said Toon Swings, PhD, Technology Expert at VIB.